

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 54431

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India

Bharat Vaswani , Sagar Bhagat , Saiprasad Patil , Hanmant Barkate

Abstract

BACKGROUND

A new, oral fixed dose combination of highly selective neurokinin-1 receptor antagonist, netupitant with 5HT₃ receptor antagonist, netupitant and palonosetron (NEPA) was approved in India for prevention of chemotherapy

Match Overview

| | | |
|---|---|-----|
| 1 | Internet 31 words crawled on 02-Feb-2020 link.springer.com | 1% |
| 2 | Internet 17 words crawled on 29-Jun-2020 www.hindawi.com | 1% |
| 3 | Internet 16 words crawled on 22-Jul-2019 e-sciencecentral.org | 1% |
| 4 | Internet 15 words crawled on 31-Mar-2020 www.ajmc.com | |
| 5 | Internet 14 words crawled on 05-Nov-2019 www.glenmarkpharma.com | <1% |
| 6 | Crossref 13 words Tsutomu Takahashi, Takahiro Okada, Fumiyoshi Ikejiri, Shun- nsuke Ito et al. "A prospective study of palonosetron for pre | <1% |
| 7 | Crossref 13 words "Recent Literature Feature Editor: Paul C. Rousseau", Journal of Palliative Medicine, 2014. | <1% |
| 8 | Internet 12 words crawled on 12-Jul-2010 www.nokc.no | <1% |

Effectiveness of a novel, fixed dose combination of netupitant



ALL

IMAGES

VIDEOS

4,750 Results

Any time ▼

Palonosetron in the prevention of chemotherapy-induced ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554402>

Aapro M, Rugo H, Rossi G, et al. A randomised phase III **study** evaluating the efficacy and safety of NEPA, a **fixed-dose combination of netupitant and palonosetron**, for **prevention of chemotherapy-induced nausea and vomiting** following moderately emetogenic chemotherapy. Ann Oncol. 2014; 25 (7):1328–1333. [PMC free article]

Cited by: 11

Author: Luigi Celio, Monica Niger, Francesca Ric...

Publish Year: 2015

Prevention of chemotherapy-induced nausea: the role of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378744>

A randomized phase III **study** evaluating the efficacy and safety of NEPA, a **fixed-dose combination of netupitant and palonosetron**, for **prevention of chemotherapy-induced nausea and vomiting** following moderately emetogenic **chemotherapy**. Ann Oncol. 2014; 25:1328–1333. doi: 10.1093/annonc /mdu101. [PMC free article] [Google Scholar]

Cited by: 12

Author: Snežana M. Bošnjak, Richard J. Gralla, L...

Publish Year: 2017



4,770 Results

Any time ▾

[Palonosetron in the prevention of chemotherapy-induced ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554402>

Aug 21, 2015 · Aapro M, Rugo H, Rossi G, et al. A randomised phase III **study** evaluating the efficacy and safety of NEPA, a **fixed-dose combination of netupitant and palonosetron**, for **prevention of chemotherapy-induced nausea and vomiting** following moderately emetogenic chemotherapy. Ann Oncol. 2014; 25 (7):1328–1333. [PMC free article]

Cited by: 12

Author: Luigi Celio, Monica Niger, Francesca Ric...

Publish Year: 2015

[Prevention of chemotherapy induced nausea and vomiting in ...](#)

<https://www.nice.org.uk/advice/esnm69/chapter/full-evidence-summary> ▾

Aapro M, Rugo H, Rossi G et al. (2014) A randomised phase III **study** evaluating the efficacy and safety of NEPA, a **fixed dose combination of netupitant and palonosetron**, for **prevention of chemotherapy-induced nausea and vomiting** following moderately emetogenic **chemotherapy**. Annals of Oncology 25: 1328–33

[\(PDF\) Profile of netupitant/palonosetron \(NEPA\) fixed dose ...](#)

<https://www.researchgate.net/publication/270343222...>

NEPA is an oral **fixed-dose combination of netupitant and palonosetron** which has recently been employed in Phase II and Phase III clinical trials for the **prevention** of CINV in patients receiving ...

[Review of oral fixed-dose combination netupitant and ...](#)

https://www.researchgate.net/publication/267744692_Review_of_oral_fixed-dose...

Netupitant is a potent and selective NK(1) receptor antagonist under development in **combination** with a **fixed dose** of **palonosetron** for the **prevention of chemotherapy induced nausea and vomiting**.

[Oncologist perspectives on chemotherapy-induced nausea and ...](#)

<https://onlinelibrary.wiley.com/doi/full/10.1002/cnr2.1127>

1 INTRODUCTION. **Chemotherapy-induced nausea and vomiting** (CINV), and **nausea** in particular, remain amongst the most dreaded and distressing side effects of anticancer treatment, negatively